Hansoh Pharma Licenses AilsynBio’s AI Platform to Discover Novel Oral Cyclic Peptide Drug Candidates

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) (HKG: 3692) announced that it has entered into a collaboration development agreement with AilsynBio, a next‑generation AI‑native biotechnology company headquartered in Hong Kong, to discover novel oral cyclic peptide drug candidates within the…

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.

More News